Latest Breaking News On - Michaelr minogue - Page 4 : comparemela.com

Abiomed (ABMD) Acquires preCARDIA

Abiomed Inc (ABMD) Q4 2021 Earnings Call Transcript

Abiomed Inc (ABMD) Q4 2021 Earnings Call Transcript Motley Fool Transcribers © The Motley Fool Logo of jester cap with thought bubble. Abiomed Inc (NASDAQ: ABMD) Operator Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter 2021 Abiomed Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to Todd Trapp. Please go ahead.SPONSORED: 10 stocks we like better than Abiomed When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.  

Abiomed Fourth Quarter Fiscal 2021 Earnings and Conference Call Notification

Abiomed Continues to Strengthen its Intellectual Property, Now Holds More Than 1,000 Patents

Press release content from Business Wire. The AP news staff was not involved in its creation. Abiomed Continues to Strengthen its Intellectual Property, Now Holds More Than 1,000 Patents January 7, 2021 GMT DANVERS, Mass. (BUSINESS WIRE) Jan 7, 2021 Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending. Abiomed’s robust intellectual property portfolio protects its current and future pump and catheter designs, along with other product components such as motors, cannulas, sensors, software, and access devices. The portfolio also protects manufacturing processes and future artificial intelligence algorithms. ADVERTISEMENT Abiomed is recognized as a leader in technology and innovation, with robust clinical data supporting the regulatory approvals and physician adoption of its technologies. The company employs several hundred engineers and scientists at its state-of-the-art research and development facil

Abiomed, Inc.: Abiomed Continues to Strengthen its Intellectual Property, Now Holds More Than 1,000 Patents

(2) Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending. Abiomed s robust intellectual property portfolio protects its current and future pump and catheter designs, along with other product components such as motors, cannulas, sensors, software, and access devices. The portfolio also protects manufacturing processes and future artificial intelligence algorithms. Abiomed is recognized as a leader in technology and innovation, with robust clinical data supporting the regulatory approvals and physician adoption of its technologies. The company employs several hundred engineers and scientists at its state-of-the-art research and development facilities in Danvers, Massachusetts, Aachen, Germany, and Berlin, Germany. Over the past 20 years, Abiomed has grown its product pipeline by investing more than $600 million in research and development.